Respiratory Syncytial Virus (RSV) is a common, highly contagious respiratory virus that infects the lungs and airways. While RSV often causes mild, cold-like symptoms in healthy adults, it can lead to severe lower respiratory tract disease in vulnerable populations—particularly infants, young children, older adults, and immunocompromised individuals.
High unmet medical need: Until recently, treatment options were limited and largely supportive (e.g. oxygen and fluids), with few targeted therapies available.
Protection of vulnerable populations: Effective vaccines and antivirals can prevent severe disease in infants, reduce hospitalisations in older adults, and protect those at high risk of complications.
Rapid disease progression: RSV can progress quickly to bronchiolitis or pneumonia, making early intervention with antivirals especially valuable.
Global health impact: RSV causes millions of lower respiratory infections annually worldwide, contributing significantly to infant mortality in low- and middle-income countries.
Preparedness and innovation: Advancing RSV vaccines and antivirals strengthens pandemic preparedness and accelerates innovation across respiratory virus research.
Together, preventive vaccines and therapeutic antivirals offer the most effective strategy to reduce RSV transmission, severity, and healthcare burden—making continued investment in RSV research and development essential.
Join our Chief Scientific Officer, Dr Andrew Catchpole, as he takes you behind the science, sharing expert insight into RSV virus isolation, GMP manufacturing, and the robust clinical data underpinning vaccine and antiviral development.
In this exclusive webinar, you’ll learn about:
Proven patient recruitment strategies at hVIVO
End-to-end human challenge trial services, from design to delivery
Advanced specialist laboratory capabilities
RSV-hMPV-PIV trivalent vaccine challenge platform readiness
Strategic clinical isolate selection
Key insights into infection dynamics, virology, and participant symptoms
Comparative data on RSV-B vs RSV-A infection and incidence rates
Contact our team to discuss how our proven expertise and innovative solutions can help accelerate your development goals.
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
